SEC Form 4 · accession 0001394548-17-000006
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rudolph Nisi
Director
Period of report
Jan 20, 2017
Accepted (ET)
Jan 24, 2017 · 6:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 20, 2017 | A | 3,262 | $1.98 | A | 4,437 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.
- F2Represents the closing stock price of the Company's stock on the first trading day of the quarter.